Mogat1 drives metabolic adaptations to evade immune surveillance

Area of Science:

• Oncology
• Immunology
• Cancer Metabolism

Background:

• Immune checkpoint blockade (ICB) therapies are crucial for treating solid tumors but frequently encounter resistance.
• Understanding novel immune evasion mechanisms beyond IFNγ signaling and antigen presentation is vital for improving ICB efficacy.

Purpose of the Study:

• To identify novel molecular targets that mediate tumor immune evasion.
• To investigate the role of lipid metabolism in fostering an immunosuppressive tumor microenvironment.
• To evaluate Monoacylglycerol O-Acyltransferase 1 (Mogat1) as a potential therapeutic target for enhancing cancer immunotherapy.

Main Methods:

• In vivo transcriptomic screening of progressing tumors to identify key modulators of immune evasion.
• Genetic inhibition of Mogat1 in tumor models.
• Assessment of tumor growth, T-cell infiltration, and anti-tumor activity.
• Evaluation of Mogat1 inhibition in combination with PD-1 blockade.

Main Results:

• Monoacylglycerol O-Acyltransferase 1 (Mogat1) was identified as a critical factor in tumor immune evasion.
• Tumors utilize Mogat1 to sequester fatty acids into triglycerides, promoting tumor growth and immune suppression.
• Genetic inhibition of Mogat1 led to reduced tumor growth, increased T-cell infiltration, and enhanced tumor-killing capacity.
• Mogat1 inhibition sensitized tumors to PD-1 blockade, overcoming resistance and reducing dependence on conventional antigen presentation.

Conclusions:

• Lipid metabolism, specifically through Mogat1, represents a novel mechanism of tumor immune evasion.
• Targeting Mogat1 can reprogram the tumor microenvironment to be more permissive to anti-tumor immunity.
• Mogat1 inhibition is a promising strategy to overcome resistance to current cancer immunotherapies, including PD-1 blockade.